12:00 AM
 | 
Oct 04, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Victoza liraglutide: Additional Phase III data

Additional data from an open-label, international Phase III trial in 665 patients inadequately controlled with metformin showed that 1.8 mg once-daily subcutaneous Victoza led to significantly higher overall treatment satisfaction as measured by Diabetes Treatment Satisfaction Questionnaire scores at week 26 vs. 100 mg once-daily oral Januvia...

Read the full 225 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >